Opportunity for ESIs attending CROI 2026 to apply to attend CFAR National Meeting + ESI Workshop
CFAR Early-Stage Investigators who will be in Denver for CROI 2026 are invited to submit a brief application to also participate in the National CFAR Meeting + ESI Workshop, held Friday–Saturday, February 20–21, 2026 at the Grand Hyatt Denver. Each CFAR is permitted to select up to two ESIs to attend.
The program includes Part 1 on Friday (plenary sessions with NIH and CFAR leaders, ESI Workshop Breakout, and Networking Reception) and Part 2 on Saturday (ESI Workshop), and offers a focused, in-person opportunity to engage with national CFAR leadership and connect with ESIs across the network.
The workshop will cover:
-
Building a successful research career
- Navigating academic advancement
- Panel discussions with CFAR leadership and community partners
- Guidance from senior investigators on mentorship, leadership development, and establishing an independent research trajectory
Please note: There will be no oral or poster presentation sessions, and abstracts are not being requested. Continental breakfast will be provided both days; lunch will be available on Friday before Part 1; beverage service (coffee, tea, water) will be available throughout. Our CFAR will additionally cover meals not provided by the conference.
For selected ESIs, CFAR will provide roundtrip flight support and hotel reimbursement for Thursday, Friday, and Saturday nights (2/19-22).
Please indicate your interest by Friday, 12/12 at 12:00 PM. Apply here
|
| |
CONGRATULATIONS!
The ARI Award for
Outstanding Research Mentoring
John Sauceda, PhD, MSc, MA
|
|
|
For demonstrating exceptional dedication and service towards advancing the scientific development and early careers of trainees working in the field of HIV/AIDS at UCSF
On behalf of the UCSF AIDS Research Institute
2025
|
|
|
Celebrating UCSF Team's publication in Nature Advancing Combined Immunotherapy Approaches for an HIV Cure
We wanted to congratulate the UCSF team on the results of the combined immunotherapy approach for HIV Cure trial published Monday in Nature and share this UCSF News Article with the UCSF HIV community. UCSF team members include: Co-first authors Michael Peluso, MD, Demi Sandel, PhD, and Amelia Deitchman, PharmD, PhD; Co-senior authors: Rachel Rutishauser, MD, PhD, and Steve Deeks, MD, along with other UCSF co-authors Steven Yukl, MD, Timothy Henrich, MD, Matthew Spitzer, PhD, David Glidden, PhD, Michiko Shimoda, PhD, Rebecca Hoh, Thomas Dalhusien, Hari Prabhath Tummala, PharmD, Sun Jin Kim, PhD, Gina Borgo, PhD, Rafael Tibúrcio, PhD, Lily Zemelko, Kaiti Schwartz, Monika Deswal, Meghan Williams, RN, and Mandana Khalili, MD.
|
|
|
Long-Term HIV Control: Could this Combination Therapy Be the Key?
This is the first study using a combination of immunotherapies in humans. The results show promise for sustained control of the virus.
A new study from UC San Francisco shows it may be possible to control HIV without long-term antiviral treatment — an advance that points the way toward a possible cure for a disease that affects 40 million people around the world.
Treatment with a combination of experimental immunotherapy agents enabled 7 out of 10 participants to keep the virus at low levels for many months after going off antiretroviral therapy (ART).
The results appear on Dec. 1, World AIDS Day, in Nature.
The trial, which relied on a collaboration with nearly a dozen pharmaceutical companies and other partners in HIV research, offers a proof of concept that the approach could work. Although the study was small and did not include a control arm, investigators said the results are extremely encouraging. Read more...
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.
|
1700 Owens Street | San Francisco, None 94158 US
|
|
|
This email was sent to .
To continue receiving our emails, add us to your address book.
|
| |
|
|
